|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
100 项与 Mediti Pharma, Inc. 相关的临床结果
0 项与 Mediti Pharma, Inc. 相关的专利(医药)
100 项与 Mediti Pharma, Inc. 相关的药物交易
100 项与 Mediti Pharma, Inc. 相关的转化医学